St. Jude Medical Inc. has finally secured an FDA advisory panel date for its Amplatzer patent foreman ovale occluder. The firm's PMA for the implant, intended to prevent recurrent stroke, will go before the agency's Circulatory System Devices panel May 24.
It has been a challenging path so far for the PFO closure device. St. Jude's 980-patient pivotal RESPECT trial missed its primary intent-to-treat endpoint in data presented in 2012, an...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?